Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
| Status: | Recruiting | 
|---|---|
| Conditions: | Cardiology, Ocular | 
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology | 
| Healthy: | No | 
| Age Range: | 50 - Any | 
| Updated: | 4/21/2016 | 
| Start Date: | September 2014 | 
| End Date: | August 2018 | 
| Contact: | Charles Johnson, MB, ChB | 
| Email: | c.johnson@neurotechusa.com | 
| Phone: | 401.495.2395 | 
A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared With Eylea for the Treatment of Recurrent CNV Secondary to AMD
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients
treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation
at year 2. Those who, in the opinion of the investigator, are still candidates for continued
anti-VEGF therapy will be re-implanted with a new NT-503-3 investigational product and
followed for an additional 12 weeks before study exit. Stage 2 (Phase II) is a separate,
randomized, masked phase during which eligible patients will be randomized to the NT-503-3
group or the control group.
Clinical Hypotheses:
- NT-503-3 ECT is comparable to Eylea® injected intravitreally every 8 weeks in the
prevention of vision loss due to recurrent CNV secondary to AMD
- NT-503-3 ECT has an acceptable safety profile
			treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation
at year 2. Those who, in the opinion of the investigator, are still candidates for continued
anti-VEGF therapy will be re-implanted with a new NT-503-3 investigational product and
followed for an additional 12 weeks before study exit. Stage 2 (Phase II) is a separate,
randomized, masked phase during which eligible patients will be randomized to the NT-503-3
group or the control group.
Clinical Hypotheses:
- NT-503-3 ECT is comparable to Eylea® injected intravitreally every 8 weeks in the
prevention of vision loss due to recurrent CNV secondary to AMD
- NT-503-3 ECT has an acceptable safety profile
Key Inclusion Criteria:
- Diagnosis of Active (recurrent or persistent) subfoveal CNV lesions secondary to AMD
in the study eye
- Prior Intravitreal Anti-VEGF injections
Key Exclusion Criteria:
- Significant subretinal hemorrhage
- Significant Scar and/or, fibrosis
- Suspected polypoidal choroidopathy, or pigment epithelial tears or rips
- Inadequate response to anti-VEGF therapy
We found this trial at
    33
    sites
	
									9500 Euclid Avenue
Cleveland, Ohio 44106
	
			Cleveland, Ohio 44106
216.444.2200
							 
					Principal Investigator: Rishi Singh, MD
			
						
										Phone: 216-445-9497
					
		Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...  
  
  Click here to add this to my saved trials
	 
  
								Ann Arbor, Michigan 48105			
	
			
					Principal Investigator: Grant Comer, MD
			
						
								Click here to add this to my saved trials
	 
  
								Asheville, North Carolina 28803			
	
			
					Principal Investigator: William Z Bridges, Jr, MD
			
						
										Phone: 828-255-8008
					Click here to add this to my saved trials
	 
  
								Augusta, Georgia 30909			
	
			
					Principal Investigator: Dennis M. Marcus, MD
			
						
										Phone: 706-650-0061
					Click here to add this to my saved trials
	 
  Click here to add this to my saved trials
	 
  
								Beverly Hills, California 90211			
	
			
					Principal Investigator: David Boyer, MD
			
						
										Phone: 310-854-6201
					Click here to add this to my saved trials
	 
  
								Bloomfield, New Jersey 07003			
	
			
					Principal Investigator: Patrick Higgins, MD
			
						
										Phone: 973-707-5632
					Click here to add this to my saved trials
	 
  
								Boston, Massachusetts 02114			
	
			
					Principal Investigator: Jeffrey S. Heier, MD
			
						
										Phone: 617-367-4800
					Click here to add this to my saved trials
	 
  
								Chesterfield, Missouri 63017			
	
			
					Principal Investigator: Nancy Holekamp, MD
			
						
										Phone: 636-728-0111
					Click here to add this to my saved trials
	 
  
								Chevy Chase, Maryland 20815			
	
			
					Principal Investigator: Michael M. Lai, MD
			
						
										Phone: 301-656-8100
					Click here to add this to my saved trials
	 
  
								Florence, South Carolina 29501			
	
			
					Principal Investigator: W. Lloyd Clark, MD
			
						
										Phone: 803-931-0077
					Click here to add this to my saved trials
	 
  
								Ft. Myers, Florida 33907			
	
			
					Principal Investigator: Alexander M Eaton, MD
			
						
										Phone: 239-337-3337
					Click here to add this to my saved trials
	 
  
								Ft. Myers, Florida 			
	
			
					Principal Investigator: Paul A Raskauskas, MD
			
						
										Phone: 239-938-1284
					Click here to add this to my saved trials
	 
  Click here to add this to my saved trials
	 
  
								Hagerstown, Maryland 21740			
	
			
					Principal Investigator: Allen Y. Hu, MD
			
						
										Phone: 310-467-4592
					Click here to add this to my saved trials
	 
  
								Irvine, California 92697			
	
			
					Principal Investigator: Baruch D. Kuppermann, MD, PhD
			
						
										Phone: 949-824-6256
					Click here to add this to my saved trials
	 
  
								Joliet, Illinois 60435			
	
			
					Principal Investigator: John S. Pollack, MD
			
						
										Phone: 815-744-7515
					Click here to add this to my saved trials
	 
  
								La Jolla, California 92093			
	
			
					Principal Investigator: William R. Freeman, MD
			
						
										Phone: 858-822-3170
					Click here to add this to my saved trials
	 
  
								Lexington, Kentucky 40509			
	
			
					Principal Investigator: Thomas W Stone, MD
			
						
										Phone: 859-263-3900
					Click here to add this to my saved trials
	 
  
								Marietta, Georgia 30060			
	
			
					Principal Investigator: Robert Stoltz, MD, PhD
			
						
										Phone: 404-299-5209
					Click here to add this to my saved trials
	 
  
								McAllen, Texas 78503			
	
			
					Principal Investigator: Victor H. Gonzalez, MD
			
						
										Phone: 956-631-8875
					Click here to add this to my saved trials
	 
  
									8701 W Watertown Plank Rd
Milwaukee, Wisconsin
	
			Milwaukee, Wisconsin
(414) 955-8296 
							 
					Principal Investigator: David Weinberg, MD
			
						
										Phone: 414-456-7840
					
		Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...  
  
  Click here to add this to my saved trials
	 
  Click here to add this to my saved trials
	 
  
								Oak Park, Illinois 60304			
	
			
					Principal Investigator: Mathew W MacCumber, MD, PhD
			
						
										Phone: 773-871-8444
					Click here to add this to my saved trials
	 
  
								Philadelphia, Pennsylvania 19107			
	
			
					Principal Investigator: Allen Ho, MD
			
						
										Phone: 215-928-3095
					Click here to add this to my saved trials
	 
  Click here to add this to my saved trials
	 
  Click here to add this to my saved trials
	 
  
								Rapid City, South Dakota 57701			
	
			
					Principal Investigator: Prema Abraham, MD
			
						
										Phone: 605-341-2000
					Click here to add this to my saved trials
	 
  
								Reno, Nevada 89502			
	
			
					Principal Investigator: Arshad Khanani, MD
			
						
										Phone: 775-329-0286
					Click here to add this to my saved trials
	 
  
								Royal Oak, Michigan 48073			
	
			
					Principal Investigator: George A. Williams, MD
			
						
										Phone: 248-551-2175
					Click here to add this to my saved trials
	 
  
								San Antonio, Texas 78240			
	
			
					Principal Investigator: Michael A Singer, MD
			
						
								Click here to add this to my saved trials
	 
  
								Winston-Salem, North Carolina 27157			
	
			
					Principal Investigator: Craig Greven, MD
			
						
										Phone: 336-716-4091
					Click here to add this to my saved trials
	 
  
								Winter Haven, Florida 33880			
	
			
					Principal Investigator: Michael Tolentino, MD
			
						
										Phone: 863-297-5400
					Click here to add this to my saved trials
	